# PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

> **NCT03543813** · PHASE1,PHASE2 · COMPLETED · sponsor: **CytomX Therapeutics** · enrollment: 133 (actual)

## Conditions studied

- Solid Tumor, Adult
- Head and Neck Cancer
- Non Small Cell Lung Cancer
- Diffuse Large B Cell Lymphoma
- Esophageal Cancer

## Interventions

- **DRUG:** CX-2029

## Key facts

- **NCT ID:** NCT03543813
- **Lead sponsor:** CytomX Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543813, "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03543813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*